BIVI net incomeQ1 2027-$5.61M
BIVI net income was -$5.61M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$5.09M a year earlier. For the full fiscal 2026 it was -$22.07M, compared with -$17.54M in fiscal 2025.
BioVie Inc. (BIVI) financials
For the twelve months ended Sep 30, 2026, BioVie Inc. reported -$22.59M of net income.
- Net income, TTM
- -$22.59M
- Cash
- $7.73M
- Market cap
- $13.6M
FY2017FY2026
BIVI revenue and earnings growth
BIVI EPSQ1 2027-$0.68
BIVI diluted EPS was -$0.68 in fiscal Q1 2027 (ended Sep 30, 2026). For the full fiscal 2026 it was -$3.05.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $13.96M | $9.27M | $23.10M | $33.30M | $17.26M | $2.54M | $1.15M | $1.01M | $370.9K | $466.4K |
| Selling, general and admin | $8.51M | $8.57M | $8.85M | $11.55M | $9.77M | $4.64M | $1.31M | $1.26M | $1.77M | $69.1K |
| Operating income | -$22.65M | -$18.07M | -$32.18M | -$45.08M | -$27.25M | -$138.05M | -$2.69M | -$2.50M | -$2.37M | -$1.55M |
| Interest expense | $17.9K | $332.7K | $2.89M | $4.30M | $2.16M | $559.5K | $4.77M | $273 | $41.0K | - |
| Net income | -$22.07M | -$17.54M | -$32.12M | -$50.26M | -$26.08M | -$130.25M | -$16.68M | -$2.44M | -$2.41M | -$1.33M |
| EPS, basic | -$3.05 | -$12.12 | -$73.05 | -$154.70 | -$106.00 | -$1482.00 | -$685.00 | -$98.00 | -$3.00 | -$1.00 |
| EPS, diluted | -$3.05 | -$12.12 | -$73.05 | -$154.70 | -$106.00 | -$1482.00 | -$685.00 | -$98.00 | -$3.00 | -$1.00 |
| Diluted shares | 7.2M | 1.5M | 451,853 | 324,834.9 | 246,625.57 | 124,031.59 | 49,294.97 | 25,396.11 | 957,580.79 | 893,913.02 |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.98M | $17.54M | $23.84M | $19.46M | $18.64M | $4.51M | $37.2K | $339.9K | $45.8K | $5.1K |
| Current assets | $13.64M | $20.70M | $24.05M | $34.04M | $18.78M | $4.61M | $413.0K | $674.1K | $45.8K | $5.1K |
| Goodwill | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K |
| Total assets | $14.25M | $21.56M | $25.21M | $35.10M | $20.11M | $6.05M | $2.08M | $2.57M | $2.18M | $2.36M |
| Current liabilities | $3.80M | $2.27M | $9.35M | $14.49M | $4.17M | $996.4K | $23.52M | $443.5K | $1.24M | $631.0K |
| Long-term debt | - | - | - | - | - | - | $62.5K | - | - | - |
| Total debt | - | - | $5.00M | - | $15.00M | - | $62.5K | - | - | - |
| Total liabilities | $3.98M | $2.55M | $9.70M | $19.76M | $16.44M | $996.4K | $23.58M | $443.5K | $2.06M | $1.21M |
| Shareholders' equity | $10.27M | $19.01M | $15.51M | $15.34M | $3.67M | $5.05M | -$21.50M | $2.13M | $111.2K | $1.16M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.02M | -$19.03M | -$27.95M | -$40.25M | -$18.99M | -$10.45M | -$1.63M | -$2.50M | -$621.3K | -$623.6K |
| Investing cash flow | - | - | $14.53M | -$14.30M | - | - | - | - | - | - |
| Financing cash flow | $10.46M | $12.73M | $17.80M | $55.37M | $33.12M | $14.93M | $1.33M | $2.80M | $662.0K | $505.0K |
| Stock-based compensation | $2.28M | $1.20M | $2.82M | $4.22M | $5.81M | $3.02M | $24.8K | $64.9K | $238.2K | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -214.9% | -92.3% | -207.1% | -327.6% | -710.6% | -2579.0% | - | -114.7% | -2170.1% | -115.0% |
| Return on assets | -154.9% | -81.4% | -127.4% | -143.2% | -129.7% | -2154.1% | -800.3% | -94.9% | -110.9% | -56.3% |
| Current ratio | 3.59 | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 | 1.52 | 0.04 | 0.01 |
| Debt to equity | - | - | 0.32 | - | 4.09 | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.34M | $3.58M | $3.18M | $4.27M | $2.94M | $1.22M | $1.34M | $4.70M | $1.99M | $2.05M | $5.70M | $6.47M |
| Selling, general and admin | $2.31M | $2.13M | $2.15M | $1.94M | $2.29M | $2.38M | $1.59M | $2.53M | $2.07M | $2.68M | $1.97M | $2.25M |
| Operating income | -$5.65M | -$5.72M | -$5.39M | -$6.26M | -$5.28M | -$3.66M | -$2.99M | -$7.29M | -$4.12M | -$4.79M | -$7.73M | -$8.78M |
| Interest expense | $968 | $4.0K | $6.0K | $6.0K | $2.0K | $5.0K | $5.0K | $66.7K | $256.0K | $439.9K | $628.7K | $820.6K |
| Net income | -$5.61M | -$5.65M | -$5.27M | -$6.07M | -$5.09M | -$3.49M | -$2.79M | -$7.11M | -$4.15M | -$4.94M | -$8.07M | -$8.40M |
| EPS, basic | -$0.68 | - | -$0.70 | -$0.77 | -$0.98 | - | -$1.51 | -$4.55 | -$7.00 | - | -$20.00 | -$22.00 |
| EPS, diluted | -$0.68 | - | -$0.70 | -$0.77 | -$0.98 | - | -$1.51 | -$4.55 | -$7.00 | - | -$20.00 | -$22.00 |
| Diluted shares | 8.3M | - | 7.5M | 7.9M | 5.2M | - | 1.9M | 1.6M | 639,836 | - | 448,010.8 | 381,707.7 |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.73M | $8.98M | $13.10M | $20.54M | $24.98M | $17.54M | $23.15M | $24.41M | $20.02M | $23.84M | $30.35M | $20.23M |
| Current assets | $10.45M | $13.64M | $16.88M | $21.79M | $26.03M | $20.70M | $23.72M | $24.68M | $20.15M | $24.05M | $30.54M | $20.56M |
| Goodwill | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K |
| Total assets | $11.04M | $14.25M | $17.51M | $22.50M | $26.82M | $21.56M | $24.66M | $25.69M | $21.24M | $25.21M | $31.77M | $21.49M |
| Current liabilities | $4.35M | $3.80M | $1.69M | $3.01M | $1.64M | $2.27M | $2.55M | $1.46M | $6.84M | $9.35M | $12.48M | $13.98M |
| Total debt | - | - | - | - | - | - | - | - | $2.50M | $5.00M | - | - |
| Total liabilities | $4.51M | $3.98M | $1.91M | $3.24M | $1.90M | $2.55M | $2.84M | $1.77M | $7.17M | $9.70M | $12.85M | $14.00M |
| Shareholders' equity | $6.53M | $10.27M | $15.61M | $19.27M | $24.92M | $19.01M | $21.82M | $23.92M | $14.07M | $15.51M | $18.93M | $7.49M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.91M | -$4.12M | -$7.44M | -$4.44M | -$3.02M | -$5.61M | -$1.25M | -$8.58M | -$3.58M | -$4.01M | -$5.85M | -$5.91M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | $0 | $0 | $0 |
| Financing cash flow | $1.66M | $0 | $0 | $0 | $10.46M | $0 | $0 | $12.97M | -$240.9K | -$2.50M | $15.98M | $4.92M |
| Stock-based compensation | $202.5K | $256.7K | $1.56M | $197.3K | $268.4K | $352.8K | $338.4K | $385.3K | $118.9K | $705.1K | $690.9K | $619.7K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.40 | 3.59 | 9.97 | 7.25 | 15.83 | 9.10 | 9.32 | 16.94 | 2.95 | 2.57 | 2.45 | 1.47 |
| Debt to equity | - | - | - | - | - | - | - | - | 0.18 | 0.32 | - | - |
Source: XBRL data BioVie Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Sep 30, 2024; 1-for-10, first reported Aug 15, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BIVI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BIVI | - | - | -$22.59M | - | $13.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
BIVI FAQ
4 questionsIs BIVI profitable?
No. BioVie Inc. reported a net loss of $22.59M for the twelve months ended Sep 30, 2026.How much cash and debt does BIVI have?
BioVie Inc. reported $7.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did BIVI last report financial results?
The latest statements here come from BioVie Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.Where does this BIVI financial data come from?
Quantisnow builds these statements from the structured XBRL data BioVie Inc. files with the SEC. It is provided for information only and is not investment advice.